DanCann Pharma A/S publishes a supplement to the prospectus for the rights issue
COPENHAGEN, Denmark, November 4, 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the “Company”), a Danish company powered by cannabinoids, hereby announces that the Company has published a supplement to the prospectus for the rights issue which was published on October 21, 2022 (the “Supplement” and the “Prospectus”). The reasons for the Supplement are the publications of the Q3-2022 report and the signing of a supply agreement with Storkpharm SP. z o.o. for the Polish Market.The Supplement, which today has been approved and registered by the Danish Financial Supervisory